Off-Hours Treatment for MS Spasticity
For acute spasticity management during off-hours in MS patients, initiate oral baclofen (starting 5mg three times daily, titrating up to 80mg/day) or tizanidine (starting 2-4mg at bedtime, titrating to effect) as first-line pharmacological options, combined with immediate physical modalities including positioning, passive stretching, and range of motion exercises. 1
Immediate Pharmacological Management
First-Line Oral Agents
The evidence supports three primary oral medications for acute spasticity management:
Baclofen: FDA-approved for spasticity, though it may cause significant sedation and has somewhat less impact in MS compared to other conditions. Start low and titrate based on response and tolerability 1, 2
Tizanidine: Preferred option with demonstrated efficacy in chronic MS patients, showing improvement in spasticity and pain without loss of motor strength. Has better tolerability profile than baclofen in many MS patients 1, 2
Gabapentin: Supported as a first-line option with evidence for MS spasticity management 2
Agents to AVOID
Explicitly avoid benzodiazepines (diazepam) during off-hours management due to deleterious effects on recovery and problematic sedation side effects, despite FDA approval for spasticity 1. This is a critical pitfall—while diazepam is technically approved, guidelines recommend against its use.
Non-Pharmacological Interventions (Implement Immediately)
These should be initiated simultaneously with any medication:
- Antispastic positioning: Proper limb positioning to reduce tone
- Passive range of motion exercises: Multiple times daily
- Stretching: Though recent evidence suggests stretching may not be more essential than simple ROM exercises, both appear beneficial 3
- Physical modalities: Consider neuromuscular electrical stimulation (NMES) or transcutaneous electrical nerve stimulation (TENS) if available, as these can temporarily improve spasticity as adjuncts 4
Clinical Decision Algorithm
Step 1: Assess severity and distribution
- Focal/localized spasticity → Consider botulinum toxin referral for next business day (not appropriate for immediate off-hours use) 4, 5
- Generalized spasticity → Oral agents appropriate
Step 2: Evaluate for exacerbating factors
- Infection (UTI, pneumonia)
- Constipation/fecal impaction
- Pressure injuries
- Pain from other sources
- Treat underlying triggers aggressively
Step 3: Select oral agent based on patient factors
- If sedation is acceptable/desired (nighttime dosing) → Tizanidine or baclofen
- If patient needs to remain alert → Gabapentin preferred
- If patient already on polypharmacy → Consider drug interactions carefully
Step 4: Dosing strategy
- Start with lowest effective dose
- Tizanidine: 2-4mg initially, can repeat every 6-8 hours, maximum 36mg/day
- Baclofen: 5mg three times daily, increase by 5mg per dose every 3 days as tolerated, usual range 30-80mg/day
- Gabapentin: 300mg at bedtime, titrate upward based on response
Important Caveats
Dantrolene is FDA-approved but has limited trial data in MS and is generally reserved for cases where other agents have failed due to its mechanism (acts peripherally on muscle) and potential hepatotoxicity 1, 2.
Intrathecal baclofen is highly effective for severe, refractory spasticity but requires specialized pump placement and is not an off-hours intervention—refer for outpatient evaluation if oral agents fail 1, 4.
Functional considerations: Not all spasticity requires aggressive treatment. Some MS patients rely on extensor tone for transfers and ambulation. Reducing spasticity may paradoxically worsen function in these cases—assess functional impact before treating 4.
When to Escalate
Refer to neurology or physiatry urgently if:
- Spasticity causing severe pain unresponsive to initial management
- Skin breakdown from positioning issues
- Contractures developing or worsening
- Generalized spasticity unresponsive to oral agents within 48-72 hours
- Need for botulinum toxin injection or intrathecal therapy consideration
The evidence base for MS spasticity management is notably limited, with most controlled trials showing reduction in tone and pain but inconsistent functional gains 1, 2, 6. However, the stepwise approach beginning with least invasive modalities and oral agents remains the standard of care for off-hours management.